<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="136">
  <stage>Registered</stage>
  <submitdate>1/11/1999</submitdate>
  <approvaldate>1/11/1999</approvaldate>
  <nctid>NCT00002590</nctid>
  <trial_identification>
    <studytitle>Combination Chemotherapy in Treating Children With Lymphoma</studytitle>
    <scientifictitle>A Pilot Study For The Treatment of Newly-Diagnosed Disseminated Anaplastic Large Cell Ki-1 Lymphoma and T-Large Cell Lymphoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CCG-5941</secondaryid>
    <secondaryid>5941</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Lymphoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - filgrastim
Treatment: drugs - cyclophosphamide
Treatment: drugs - cytarabine
Treatment: drugs - daunorubicin hydrochloride
Treatment: drugs - doxorubicin hydrochloride
Treatment: drugs - etoposide
Treatment: drugs - leucovorin calcium
Treatment: drugs - methotrexate
Treatment: drugs - pegaspargase
Treatment: drugs - prednisone
Treatment: drugs - thioguanine
Treatment: drugs - vincristine sulfate
Treatment: other - radiation therapy

Experimental: Regimen A - See detailed description.


Other interventions: filgrastim


Treatment: drugs: cyclophosphamide


Treatment: drugs: cytarabine


Treatment: drugs: daunorubicin hydrochloride


Treatment: drugs: doxorubicin hydrochloride


Treatment: drugs: etoposide


Treatment: drugs: leucovorin calcium


Treatment: drugs: methotrexate


Treatment: drugs: pegaspargase


Treatment: drugs: prednisone


Treatment: drugs: thioguanine


Treatment: drugs: vincristine sulfate


Treatment: other: radiation therapy


</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Estimate toxicity and feasibility of 11 month multiagent chemotx - Estimate the toxicity and feasibility of a short (11 month) aggressive multiagent chemotherapy regimen - Intensive NYI\NHL</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Provide preliminary data for a future phase III study</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Investigate the biology of lymphoblastic lymphoma - To continue to investigate the biology of lymphoblastic lymphoma and its relationship to leukemia through the study of immunophenotyping, cytogenetics and molecular analysis.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Obtain preliminary data on treatment of anaplastic large cell - To obtain preliminary data on treatment of anaplastic large cell (Ki-1) and T-cell large cell lymphoma treated with intensive NYI.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS: Histologically confirmed and previously untreated anaplastic large
        cell Ki-1 lymphoma and T-cell large cell lymphoma Malignant lymphoblasts (identified by
        immunophenotype) in pleural fluid, ascitic fluid, or bone marrow sufficient for diagnosis
        Large cell lymphoma with T-cell phenotype eligible Localized mediastinal disease and bone
        lymphoma eligible CNS disease eligible and defined as: Any clearly identifiable tumor cells
        in cerebral spinal fluid Cranial nerve palsy (if not explained by extra cranial tumor)
        Clinical Spinal Cord Compression Isolated intra cerebral mass No cranial nerve palsies
        requiring immediate CNS irradiation

        PATIENT CHARACTERISTICS: Age: Under 21 Performance status: Not specified Hematopoietic: Not
        specified Hepatic: Not specified Renal: Not specified Cardiovascular: Shortening fraction
        greater than 27% on echocardiogram (ECHO) OR Left ventricular ejection fraction greater
        than 47% on radionuclide scan (RCNA) OR Cardiac function assessed as within normal limits
        by cardiologist ECHO or RCNA obtained as close as clinically possible to start of therapy

        PRIOR CONCURRENT THERAPY: No prior therapy except emergency treatment of airway obstruction
        or superior vena cava syndrome No more than 72 hours between emergency radiotherapy or
        steroids and initiation of protocol therapy</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>20</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/1994</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>221</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2007</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Princess Margaret Hospital for Children - Perth</hospital>
    <postcode>6001 - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Children's Oncology Group</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Cancer Institute (NCI)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining more than one drug may kill more tumor cells.

      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating
      children who have lymphoma.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00002590</trialwebsite>
    <publication>Lones MA, Perkins SL, Sposto R, Tedeschi N, Kadin ME, Kjeldsberg CR, Wilson JF, Zwick DL, Cairo MS. Non-Hodgkin's lymphoma arising in bone in children and adolescents is associated with an excellent outcome: a Children's Cancer Group report. J Clin Oncol. 2002 May 1;20(9):2293-301.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Minnie Abromowitch, MD</name>
      <address>Children's Hospital Medical Center, Cincinnati</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>